Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 35 | 2024 | 2278 | 3.840 |
Why?
|
| Adenocarcinoma | 40 | 2023 | 7789 | 2.990 |
Why?
|
| Esophageal Neoplasms | 33 | 2023 | 3168 | 2.780 |
Why?
|
| Gastrectomy | 8 | 2024 | 451 | 1.820 |
Why?
|
| Esophagogastric Junction | 11 | 2021 | 543 | 1.800 |
Why?
|
| Chemoradiotherapy | 20 | 2022 | 1946 | 1.220 |
Why?
|
| Chemoradiotherapy, Adjuvant | 9 | 2022 | 565 | 1.050 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2022 | 5437 | 1.050 |
Why?
|
| Esophagectomy | 10 | 2021 | 911 | 0.930 |
Why?
|
| Peritoneal Neoplasms | 6 | 2024 | 821 | 0.850 |
Why?
|
| Neoadjuvant Therapy | 15 | 2022 | 4975 | 0.800 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2022 | 3890 | 0.730 |
Why?
|
| Hyperthermia, Induced | 2 | 2024 | 510 | 0.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2024 | 15862 | 0.650 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 275 | 0.480 |
Why?
|
| Fluorouracil | 6 | 2020 | 1944 | 0.440 |
Why?
|
| Combined Modality Therapy | 14 | 2024 | 8865 | 0.440 |
Why?
|
| Oxonic Acid | 1 | 2011 | 24 | 0.400 |
Why?
|
| Tegafur | 1 | 2011 | 50 | 0.400 |
Why?
|
| Neoplasm Staging | 15 | 2021 | 13658 | 0.400 |
Why?
|
| Lymph Node Excision | 2 | 2021 | 1959 | 0.370 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 1299 | 0.350 |
Why?
|
| Humans | 63 | 2024 | 261506 | 0.300 |
Why?
|
| Survival Rate | 12 | 2024 | 12221 | 0.300 |
Why?
|
| Aged | 33 | 2022 | 70117 | 0.300 |
Why?
|
| Middle Aged | 37 | 2023 | 86204 | 0.300 |
Why?
|
| Paclitaxel | 3 | 2020 | 1996 | 0.290 |
Why?
|
| Prognosis | 18 | 2023 | 21713 | 0.280 |
Why?
|
| Camptothecin | 2 | 2020 | 517 | 0.270 |
Why?
|
| Aged, 80 and over | 20 | 2022 | 29902 | 0.270 |
Why?
|
| Induction Chemotherapy | 2 | 2020 | 669 | 0.270 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 14889 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 4367 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 10035 | 0.250 |
Why?
|
| Preoperative Care | 2 | 2021 | 1529 | 0.240 |
Why?
|
| Male | 37 | 2021 | 123000 | 0.240 |
Why?
|
| Antineoplastic Agents | 8 | 2022 | 14289 | 0.240 |
Why?
|
| Adult | 26 | 2021 | 77950 | 0.230 |
Why?
|
| Receptor, ErbB-2 | 2 | 2023 | 2518 | 0.230 |
Why?
|
| Trastuzumab | 3 | 2017 | 696 | 0.230 |
Why?
|
| Capecitabine | 2 | 2017 | 388 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2019 | 3251 | 0.220 |
Why?
|
| Treatment Outcome | 15 | 2020 | 32848 | 0.220 |
Why?
|
| Female | 37 | 2021 | 141928 | 0.220 |
Why?
|
| Esophagoscopy | 2 | 2012 | 291 | 0.220 |
Why?
|
| Perfusion | 2 | 2024 | 293 | 0.220 |
Why?
|
| Cisplatin | 3 | 2020 | 2432 | 0.210 |
Why?
|
| Retrospective Studies | 24 | 2023 | 37905 | 0.200 |
Why?
|
| Disease-Free Survival | 10 | 2020 | 10001 | 0.200 |
Why?
|
| Prospective Studies | 9 | 2022 | 12873 | 0.200 |
Why?
|
| Perineum | 1 | 2021 | 107 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 6207 | 0.180 |
Why?
|
| Salvage Therapy | 5 | 2017 | 2054 | 0.180 |
Why?
|
| Lymph Nodes | 2 | 2021 | 2967 | 0.180 |
Why?
|
| Phenotype | 1 | 2011 | 6295 | 0.180 |
Why?
|
| Positron-Emission Tomography | 5 | 2015 | 2173 | 0.180 |
Why?
|
| Nomograms | 2 | 2012 | 313 | 0.180 |
Why?
|
| Platinum Compounds | 2 | 2017 | 131 | 0.180 |
Why?
|
| Mitomycin | 1 | 2020 | 208 | 0.170 |
Why?
|
| Patient Selection | 2 | 2017 | 2055 | 0.170 |
Why?
|
| Taxoids | 3 | 2017 | 967 | 0.160 |
Why?
|
| Biomarkers, Tumor | 3 | 2022 | 10331 | 0.160 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 4988 | 0.150 |
Why?
|
| Remission Induction | 4 | 2017 | 3569 | 0.150 |
Why?
|
| Barrett Esophagus | 2 | 2018 | 569 | 0.140 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 884 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1331 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 1547 | 0.140 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1021 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 272 | 0.130 |
Why?
|
| Organoplatinum Compounds | 2 | 2015 | 702 | 0.130 |
Why?
|
| Treatment Refusal | 2 | 2013 | 128 | 0.130 |
Why?
|
| Endoscopy | 1 | 2018 | 479 | 0.130 |
Why?
|
| Esophagus | 1 | 2018 | 553 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 833 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 1085 | 0.120 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 1742 | 0.110 |
Why?
|
| Texas | 3 | 2020 | 6311 | 0.110 |
Why?
|
| Lymphatic Metastasis | 4 | 2021 | 4844 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 447 | 0.110 |
Why?
|
| Risk Factors | 5 | 2015 | 17523 | 0.110 |
Why?
|
| Carcinoma | 1 | 2024 | 2578 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 3719 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 756 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2017 | 650 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2330 | 0.090 |
Why?
|
| Young Adult | 7 | 2021 | 21445 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 1248 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 5112 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 621 | 0.090 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 1516 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2020 | 9180 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4849 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 12926 | 0.080 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 716 | 0.080 |
Why?
|
| Disease Management | 1 | 2013 | 1052 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4298 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4892 | 0.070 |
Why?
|
| Hospitalization | 1 | 2015 | 2083 | 0.070 |
Why?
|
| Treatment Failure | 3 | 2014 | 1391 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 11538 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2021 | 9244 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2011 | 1353 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5319 | 0.060 |
Why?
|
| Genes, erbB | 1 | 2023 | 26 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 3981 | 0.050 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2022 | 76 | 0.050 |
Why?
|
| Preoperative Period | 2 | 2013 | 344 | 0.050 |
Why?
|
| Neoplasms | 2 | 2023 | 15193 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 285 | 0.050 |
Why?
|
| Nausea | 1 | 2023 | 525 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 371 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2013 | 1258 | 0.050 |
Why?
|
| ErbB Receptors | 2 | 2023 | 2295 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2024 | 475 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2020 | 2218 | 0.040 |
Why?
|
| Logistic Models | 2 | 2020 | 3441 | 0.040 |
Why?
|
| Diarrhea | 1 | 2023 | 686 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 332 | 0.040 |
Why?
|
| Ploidies | 1 | 2019 | 248 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 233 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 980 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2021 | 668 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 5159 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 6869 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2021 | 641 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 1033 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 4557 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 651 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 470 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 1533 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 8873 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 280 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1987 | 0.030 |
Why?
|
| Disease Progression | 2 | 2018 | 6682 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 2594 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 1910 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 1 | 2013 | 183 | 0.030 |
Why?
|
| Drug Approval | 1 | 2014 | 178 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 699 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 2086 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2012 | 134 | 0.030 |
Why?
|
| Adolescent | 1 | 2012 | 31252 | 0.030 |
Why?
|
| Mutation | 2 | 2023 | 15179 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 665 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 4938 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2011 | 205 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 945 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 419 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 550 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 15694 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 472 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1287 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 1382 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 1904 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 482 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 4757 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3045 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 2231 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 1824 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 3443 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 3260 | 0.010 |
Why?
|
| United States | 1 | 2021 | 15433 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 1544 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 5673 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2011 | 1423 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 5178 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 11965 | 0.010 |
Why?
|